mick
1年前
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:
https://www.wallstreetreporter.com/2022/05/31/next-super-stock-ai-ml-billion-dollar-patent/
AIMLF’s Health Gauge subsidiary, has recently been granted a patent by the
United States Patent and Trademark Office (US Patent No. 11183303),
titled "Wearable Health Monitors and Methods of Monitoring Health".
The Patent covers Cardiovascular monitoring, Predictive health analysis, Behavioral analysis and 64 other claims,
including use of multiple configurations of wearable health monitors, in conjunction with methods of analyzing bio-signals
and monitoring health metrics (via Health Gauge's AI-driven software) for the purpose of assisting the user in achieving
their personal health and wellness objectives.
AIMLF is reporting advancing growth at its portfolio company Tech2Heal, a European mental health app innovator.
Tech2Heal is positioned for explosive revenue growth
as European healthcare mandates now provide about 2,500 Euro per patient annually for mental wellness.
Tech2Heal has just signed with a French multinational manufacturer, to provide mental wellness
support to their 170,000 employees globally, and additional Enterprise contracts are in the pipeline.
Tim Daniels also updated investors on AIML’s growing pipeline of M&A opportunities in the HealthTech space, which could have a positive impact on maximizing shareholder value in coming months.
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:
https://www.wallstreetreporter.com/2022/05/31/next-super-stock-ai-ml-billion-dollar-patent/
mick
1年前
AI/ML Innovations (OTC: AIMLF) (CSE: AIML) Chairman, Tim Daniels: “AI/ML Holds Key Patents
for Multi-Billion Dollar Healthcare Wearables Market”
AI/ML Innovations (OTC: AIMLF), a featured presenter at Wall Street Reporter's "Next Super Stock"
investor conference series, recently updated investors on growth initiatives at AIMLF’s portfolio of
digital health businesses including HealthGauge, a wearable personal health monitoring & management system,
using Artificial Intelligence and Machine Learning, and Tech2Heal a European mental health app innovator.
Of significant interest for investors is AIMLF’s landmark patent position for wearable health monitors -
which could position AIMLF to collect licensing fees and royalties on the $13.8 Billion global
Smart Wearable Healthcare Devices (projected to reach $37.4 Billion by 2028.
Source: Verified Market Research.) AIMLF is now starting to license its technologies to health wearables companies,
and collecting royalties.
With typical royalties of 2% of gross sales,
AIMLF could potentially generate significant recurring revenues from companies infringing on
its broad patent position in the nearly $14 billion health wearables market.
Watch AI/ML Innovations (OTC: AIMLF) (CSE: AIML) NEXT SUPER STOCK Video:
https://www.wallstreetreporter.com/2022/05/31/next-super-stock-ai-ml-billion-dollar-patent/4
mick
1年前
AI/ML INNOVATIONS INC.
AI/ML Innovations’ Strategic Partner, Tech2Health, Projects
https://aiml-innovations.com/wp-content/uploads/2021/09/AIML-News-Release-July-14-2021.pdf
US$5M Revenue from its First Commercial Contracts
-3 multi-year contracts signed in the first month of operation-
- digital mental health services contracts provide access to 300,000 potential usersJuly 14, 2021 ACCESSWIRE
AI/ML Innovations Inc. (CSE: AIML) (OTCQB: AIMLF) (“AIML” or the “Company”), a company
committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address
urgent societal needs, is pleased to announce that its strategic partner, Tech2Health, a France-based global
provider of proprietary digital mental health and wellness products, has entered into commercial contracts
with three companies to provide digital mental health services to their employees and insured members.
Based on the number of individuals covered and standard industry usage rates, Tech2Health estimates that
these contracts may potentially generate an aggregate total of US$5 million of revenue over the 3-year life
of the contracts. AIML has a binding Letter of Intent to acquire a 70% undivided interest in the North
American rights to Tech2Health’s complete portfolio of products and brands, in addition to a 22.22% equity
interest in Tech2Health’s global operations.
Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
